Genetic Engineering News, May 2007
Point of View
Remedy: More Brainpower, Less Hype
George L. Gabor Miklos, Ph.D., is director of Secure Genetics, Sydney. Web: www.securegenetics.com. Phillip J. Baird, M.D., Ph.D., is principle pathologist and CEO of Integrated Diagnostic Pathology, Sydney. For more information, visit: "You Bet Your Life".
It’s easy to tell when an area has run out of ideas. The hype becomes extreme, and technology substitutes for brainpower. The cancer research area has reached this sorry state. The tiniest increase in the survival time of drug treated cancer patients or median time to progression is touted as a cure, and wildly unrealistic claims about personalized cancer medicine emanate from the highest governmental and academic sources. In contrast, Andy Grove, the former Chairman and CEO of Intel, who has tried to shake this dysfunctional cancer mindset. “In cancer, everybody plays his individual part to perfection, everybody does what’s right by his own life, and the total just doesn’t work.”
How have we reached this low point where a generation of young scientists, biotechnologists, and the massive resources of big pharma are basically running on vapor? The answers are not hard to find. First, understanding some basic clinical facts is a good place to start. Second, clinically irrelevant research avenues need to be jettisoned—pronto. Resources and intellectual horsepower need to flow into areas that have clinical impact. Broadly speaking, cancers come in two forms, solid tumors, which make up 90% of cancers, and liquid tumors, such as leukemias. Most cancer patients do not die from the primary tumor; 90% die as a result of metastasis, which causes organs to shut down over a number of years. The rogue cells that leave home are genomically different than those that remain, a finding based on clinical data from single-cell analyses of breast cancer patients by Riethmuller and Klein. Furthermore, primary tumors are highly heterogeneous. Samples taken from different regions of the same tumor have cancer cells that differ enormously at the genomic and transcriptomic levels. In addition, treating any cancer with drugs unavoidably selects for those cells that are, or can become, drug-resistant. Thus when drug treatment is stopped, the cancer returns in a more dangerous drug-resistant form.
A recent, in-depth analysis by members of Amgen and Novartis on why cancer drug discovery is so difficult shows that there have only been incremental improvements in treatment outcomes. Oncology is close to having the worst record for investigational drugs in clinical development, with a success rate three times lower than cardiology. Meanwhile, the price tag for front-line cancer therapy has become astronomical. The clinical reality for metastatic colorectal cancer is that the FDA-approved combination regimen of IFL (irinotecan, bolus fluorouracil, and leucovorin) plus Avastin increases median overall survival by 4.7 months. This small increase comes with a host of side effects, which impinge upon quality of life, as well as placing a burden on the patient and the healthcare system. While this small increase is hailed by the FDA as being impressive, the clinical reality is that there is no cure for metastatic colorectal cancer. The much vaunted blockbuster drug Avastin is simply an antibody supplement incorporated into an already complex chemotherapeutic drug regimen that may slow down the cancer process depending on the genetic constitution of that individual. The cost of drugs for metastatic colorectal cancer alone would exceed $1.5 billion per year if all the patients in the U.S. received treatment.
The clinical reality for metastatic breast cancer is similar.The latest treatment with Herceptin followed by lapatinib and capecitabine only increased the median time to progression from 4.4 to 8.4 months. Furthermore, 70% of patients do not respond to Herceptin, and resistance develops in virtually all patients. Of these two big killers, both remain incurable, and this sobering fact contrasts with the glowing reports on Avastin and Herceptin emanating from the financial and tabloid media. The much touted success of Gleevec for the rare liquid cancer Chronic Myelogenous Leukemia (CML) is not generalizable to solid tumors; resistance to Gleevec in CML develops rapidly, as does resistance to nearly every tested cancer drug. Many of the initial responders to Gleevec in blast crisis relapse within months, and the growing consensus is that Gleevec is an exception, rather than a new paradigm. The Gleevec case should be seen in its proper clinical perspective, namely a treatment that largely involves single cells amenable to attack because of their presence in the circulation. Metastatic tumors, which cause 90% of all deaths, by contrast have hundreds to thousands of surgically inaccessible growths dispersed throughout an organ; they cannot be attacked out in the open as is the case with tumor cells in the circulation. There is little point in singing the praises of Gleevec and pretending that it is a proof of principle for solid tumors.
So what are the responses of government agencies and academic institutions to this clinical reality? They are simplistic: well, yes, progress is slow, it’s a complex problem, but we are moving in the right direction. If billions of dollars are poured into DNA sequencing of primary tumors, then we hope to find the critical mutations that cause cancer and then make drugs to them, so that each patient can have a unique treatment. And lets not forget, the Human Genome Project was such an outstanding success that we can simply do the same thing for cancer by hyping a Cancer Genome Project. The public will love it, the scientists will love it, and the taxpayer will assuredly fund it. [Continued]